CME Presentations

HER Directed Cancer Therapy


Presentations


Speakers

  • Stephen Liu, MD

    Stephen Liu, MD

    Stephen Liu, MD

    Stephen V. Liu, MD, is associate professor of medicine, director of Thoracic Oncology, and director of Developmental Therapeutics at the Lombardi Comprehensive Cancer Center of Georgetown University in Washington DC. His research focus is on the development of novel therapeutic agents and combinations for the treatment of advanced thoracic malignancies. Dr Liu’s work has been published in many journals including the New England Journal of Medicine and the Journal of Clinical Oncology. In addition to leading national and global clinical trials for the treatment of lung cancer, he has served as the chief editor for Frontiers in Thoracic Oncology since 2014. Dr Liu received his internal medicine training at the University of Pennsylvania in Philadelphia.
  • Adam Brufsky, MD, PhD

    Adam Brufsky, MD, PhD

    Adam Brufsky, MD, PhD

    Adam M. Brufsky, MD, PhD, is professor of medicine and associate division chief for the Division of Hematology/Oncology at the University of Pittsburg School of Medicine in Pennsylvania. He serves as co-director of the Comprehensive Breast Cancer Center and medical director of the Women’s Cancer Center at the UPMC Magee-Women’s Hospital. Dr Brufsky is the principal investigator on a number of research grants funded by the National institute of Health and the Susan G. Komen Foundation. He has authored or co-authored numerous abstracts and research articles in prominent journals, including the New England Journal of Medicine. Dr Brufsky is an active member of the American Society of Clinical Oncology and the American Association for Cancer Research.

CME Information

Updates in Metastatic HER2 Breast Cancer Management


Global Logo PQH Logo

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

  • Evaluate clinical trial data for recently approved HER2-targeting agents for the management of metastatic HER2 breast cancer
  • Discuss management strategies for adverse effects associated with recently approved agents for HER2 breast cancer
  • Assess the therapeutic implications of ongoing clinical trials for emerging agents that target HER
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC

ACKNOWLEDGEMENT

This activity is supported by an educational grant from Daiichi Sankyo, Inc.

TERM OF OFFERING

This activity was released on September 21, 2020 and is valid for one year. Requests for credit must be made no later than September 21, 2021.

TARGET AUDIENCE

The educational design of this activity addresses the needs of medical oncologists (including breast, thoracic, gastrointestinal), pharmacists, advanced practice providers (NPs and PAs), and other HCPs involved in the treatment of patients with HER-mutated cancers.

STATEMENT OF NEED/PROGRAM OVERVIEW

The long-term prognosis for patients with HER-expressing tumors has significantly improved with the availability of HER2-targeted therapy. In these back-to-back virtual events, Dr. Adam Brufsky and Dr. Stephen Liu will take us on a journey of how to effectively optimize the use of HER-directed agents and their emerging clinical applications.

In session 1, hear from these experts on the potential heterogeneity of HER2 status, the relationship between HER2 and HER3, and the molecular mechanisms that give rise to HER2 treatment resistance. Delve into the role of HER2/3 in multiple solid-tumor types (including NSCLC, gastric cancer, and CRC); review emerging clinical data for HER2/3-directed therapy; and receive guidance for overcoming treatment resistance to optimize patient outcomes.

In session 2, join Dr. Brufsky and Dr. Liu again as they review the most recent clinical-trial data on recently approved and investigational HER2-directed agents. A patient case will help guide the discussion of efficacy and safety data, treatment selection, and side-effect management.

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

ACPE Logo

Pharmacist Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

Global Education Group designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-20-096-H01-P)
This is a knowledge-based activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 1 hour to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive CE credit, participants must receive a minimum score of 70% on the post-test. For pharmacist learners, please check the CPE monitor within 60 days of the activity.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Adam M. Brufsky, MD, PhD
Professor of Medicine,
University of Pittsburgh School of Medicine;
Associate Director of Clinical Investigation,
University of Pittsburgh Cancer Institute
Consultant/Independent Contractor: Seattle Genetics, Daiichi, AstraZeneca, Puma, Roche
Stephen V. Liu, MD
Associate Professor of Medicine, Director of Thoracic Oncology,
Director of Developmental Therapeutics,
Lombardi Comprehensive Cancer Center of Georgetown University
Consultant/Independent Contractor: AstraZeneca, Boehringer-Ingelheim, Celgene, Genentech/Roche, MSD, Pfizer
Grant/Research Support: Alkermes, AstraZeneca, Bayer, Blueprint, Bristol-Myers Squibb, Corvus, Genentech, Lilly, Lycera, Merck, Merus, Molecular Partners, Pfizer, Rain, RAPT, Spectrum, Turning Point Therapeutics (all to institution)
Advisory Board: AstraZeneca, Blueprint, Bristol-Myers Squibb, Catalyst, Celgene, G1 Therapeutics, Genentech/Roche, Guardant Health, Janssen, Lilly, LOXO, PharmaMar, Regeneron, Takeda


The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner or Manager Reported Financial Relationship
Ashley Marostica, RN, MSN Nothing to disclose
Lindsay Borvansky Nothing to disclose
Andrea Funk Nothing to disclose
Liddy Knight Nothing to disclose
Ashley Cann Nothing to disclose
Tariqa Ackbarali Nothing to disclose
Elizabeth del Nido Nothing to disclose

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Technical Support:
For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.

Targeting HER2/HER3 in HER-Expressing Tumor Types


Global Logo PQH Logo

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

  • Describe the relationship between HER2 and HER3 and potential mechanisms that result in resistance to agents targeting HER2
  • Review HER2 testing guidelines with a focus on identifying low HER2 disease
  • Discuss the role of HER2/HER3 overexpression in multiple tumor types, such as gastric, colorectal, and NSCLC
  • Explain the mechanism of action of investigational agents targeting HER2/HER3
  • Compare the efficacy and safety data for emerging HER2/Her3-directed therapies
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC

ACKNOWLEDGEMENT

This activity is supported by an educational grant from Daiichi Sankyo, Inc.

TERM OF OFFERING

This activity was released on September 21, 2020 and is valid for one year. Requests for credit must be made no later than September 21, 2021.

TARGET AUDIENCE

The educational design of this activity addresses the needs of medical oncologists (including breast, thoracic, gastrointestinal), pharmacists, advanced practice providers (NPs and PAs), and other HCPs involved in the treatment of patients with HER-mutated cancers.

STATEMENT OF NEED/PROGRAM OVERVIEW

The long-term prognosis for patients with HER-expressing tumors has significantly improved with the availability of HER2-targeted therapy. In these back-to-back virtual events, Dr. Adam Brufsky and Dr. Stephen Liu will take us on a journey of how to effectively optimize the use of HER-directed agents and their emerging clinical applications.

In session 1, hear from these experts on the potential heterogeneity of HER2 status, the relationship between HER2 and HER3, and the molecular mechanisms that give rise to HER2 treatment resistance. Delve into the role of HER2/3 in multiple solid-tumor types (including NSCLC, gastric cancer, and CRC); review emerging clinical data for HER2/3-directed therapy; and receive guidance for overcoming treatment resistance to optimize patient outcomes.

In session 2, join Dr. Brufsky and Dr. Liu again as they review the most recent clinical-trial data on recently approved and investigational HER2-directed agents. A patient case will help guide the discussion of efficacy and safety data, treatment selection, and side-effect management.

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

ACPE Logo

Pharmacist Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

Global Education Group designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-20-094-H01-P)
This is a knowledge-based activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 1 hour to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive CE credit, participants must receive a minimum score of 70% on the post-test. For pharmacist learners, please check the CPE monitor within 60 days of the activity.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Adam M. Brufsky, MD, PhD
Professor of Medicine,
University of Pittsburgh School of Medicine;
Associate Director of Clinical Investigation,
University of Pittsburgh Cancer Institute
Consultant/Independent Contractor: Seattle Genetics, Daiichi, AstraZeneca, Puma, Roche
Stephen V. Liu, MD
Associate Professor of Medicine, Director of Thoracic Oncology,
Director of Developmental Therapeutics,
Lombardi Comprehensive Cancer Center of Georgetown University
Consultant/Independent Contractor: AstraZeneca, Boehringer-Ingelheim, Celgene, Genentech/Roche, MSD, Pfizer
Grant/Research Support: Alkermes, AstraZeneca, Bayer, Blueprint, Bristol-Myers Squibb, Corvus, Genentech, Lilly, Lycera, Merck, Merus, Molecular Partners, Pfizer, Rain, RAPT, Spectrum, Turning Point Therapeutics (all to institution)
Advisory Board: AstraZeneca, Blueprint, Bristol-Myers Squibb, Catalyst, Celgene, G1 Therapeutics, Genentech/Roche, Guardant Health, Janssen, Lilly, LOXO, PharmaMar, Regeneron, Takeda


The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner or Manager Reported Financial Relationship
Ashley Marostica, RN, MSN Nothing to disclose
Lindsay Borvansky Nothing to disclose
Andrea Funk Nothing to disclose
Liddy Knight Nothing to disclose
Ashley Cann Nothing to disclose
Tariqa Ackbarali Nothing to disclose
Elizabeth del Nido Nothing to disclose

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Technical Support:
For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.